Eevia Health Plc confirms a top-ranking performance of key products in a broad scientific study by Eurofins, comparing against competitor alternatives
Eevia Health Plc, ("Eevia" or "The Company") has undertaken a broad in vitro study in cooperation with Eurofins to benchmark Eevia’s extracts against the presumably strongest competitor products. The study showed that Eevia’s extracts performed as well or better than the competitors. As an example, Eevia’s Fenoprolic 70 Organic showed better bioactivity than the best-selling pine bark extract in the industry.The study of the bioactivity of the Eevia top extracts was done on Eurofin’s BioMAP® Human Primary Cell Phenotypic profiling platform. The Eurofins platform contains over 150 biomarkers
Company release, Inside information11 September 2023 at 12:30 (EEST)
Nightingale Health Plc’s (“Nightingale Health”) Board of Directors has approved an updated strategy which focuses on business to business (“B2B”) and business to governments (“B2G”) markets. The updated strategy builds on the significant contracts that the company has recently won and market feedback about the company’s strengths. Moreover, the updated strategy allows Nightingale Health to better focus and allocate its resources around its core intellectual property assets, competencies, and value creation